Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 10/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.40 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | BUB1 | O43683 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051461 | 0.81 | GSK3B (0.45) | PIK3C3MAPK8MAPK9MAPK10TGFBR1 | |
| SCHEMBL6842878 | 0.77 | MAPK14 (0.49) | PIK3C3MAPK8MAPK9MAPK10GSK3B | |
| SCHEMBL15076909 | 0.76 | PIK3C3 (0.47) | PIK3C3GSK3BMAPK14PIP5K1CPIK3CA | |
| SCHEMBL15051389 | 0.72 | MAPK14 (0.37) | PIK3C3MAPK8MAPK9MAPK10GSK3B | |
| SCHEMBL954822 | 0.70 | MAPK14 (0.45) | PIK3C3MAPK8MAPK9MAPK10TGFBR1 | |
| SCHEMBL953124 | 0.69 | MAPK14 (0.47) | PIK3C3MAPK8MAPK9MAPK14PIP5K1C | |
| SCHEMBL15051294 | 0.69 | NR3C2 (0.51) | PIK3C3TGFBR1TGFBR2 | |
| SCHEMBL12947666 | 0.68 | PIK3C3 (0.44) | PIK3C3TGFBR1GSK3BMAPK14PIP5K1C | |
| SCHEMBL25209860 | 0.67 | CCNB2 (0.51) | PIK3C3GSK3BGSK3A | |
| SCHEMBL15051235 | 0.67 | PIK3C3 (0.43) | PIK3C3GSK3BMAPK14BUB1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | claimed |
| EP-2793879-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | PIK3C3 143/4885MAPK8 543/4885MAPK9 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.